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PMH21
CLINICAL AND HEALTH-RELATED QUALITY OF 
LIFE OUTCOMES ASSOCIATED WITH 
OLANZAPINE IN PATIENTS WITH BIPOLAR 
DISORDER AS COMPARED WITH HALOPERIDOL
Shi L1, Namjoshi M1, Zhang F1, Edgell E2, Tohen M1
1Lilly Research Laboratories, Indianapolis, IN, USA; 2 Lilly 
Research Centre, Windlesham, UK
OBJECTIVE: To compare the clinical and health-related
quality of life outcomes associated with olanzapine and
haloperidol treatment in patients with bipolar disorder.
METHODS: Patients (N  453) with bipolar I disorder
(manic or mixed episode) were randomized to either
olanzapine 5–20 mg/day or haloperidol 3–15 mg/day for
12 weeks. The primary clinical outcome was the symp-
tomatic remission rates, as defined a priori by the propor-
tion of patients having a Y-MRS total score 12 and a
HAMD-21 total score  8, at 6 weeks and 12 weeks. The
humanistic outcomes were measured as changes from
baseline to endpoint (week 6 or week 12) in the scores of
the Medical Outcomes Study 36-Item Short Form Health
Survey (SF-36).
RESULTS: Olanzapine-treated patients had a higher re-
mission rate than haloperidol at six weeks (52% versus
46% p  0.15) and at 12 weeks (52% versus 44%, p 
0.08). At week six, significant changes in five SF-36 do-
mains of general health (p  0.010), physical functioning
(p  .001), role limitations due to physical health prob-
lems (p  .001), social functioning (p  .05), and vitality
(p  .01), were found in favor of olanzapine-treated pa-
tients as compared to haloperidol. At week 12, olanza-
pine treatment maintained the significantly favorable changes
in the same domains with the exception of social functioning.
None of the SF-36 domains was in favor of haloperidol at
week 6 or week 12.
CONCLUSIONS: Compared to haloperidol, olanzapine
treatment was associated with the improvements in the
clinical and health-related quality of life outcomes in pa-
tients with bipolar disorder. STATEMENT OF SIGNIFI-
CANCE: Compared to haloperidol, olanzapine treatment
was associated with the improvements in the clinical and




THE USE OF NEFAZODONE IN THE 
TREATMENT OF POST TRAUMATIC 
STRESS DISORDER
Voris JC1, Voris CT2, Kaltsounis J3
1University of South Carolina, Columbia, SC, USA; 2Dorn 
Veterans Hospital, Columbia, SC, USA; 3Bristol-Meyers Squibb 
Co, New York, NY, USA
OBJECTIVE: Examine the utilization and daily dose of
nefazodone compared to that of three SSRIs (fluoxetine,
paroxetine, and sertraline) in the treatment of PTSD and
depression at the Dorn Veterans Medical Center, a hospi-
tal for military veterans.
METHODS: A total of 1761 patients received an SSRI or
nefazodone during the month of December 1999. Fifty
patients from each drug group were randomly selected.
Information on diagnosis and dose were extracted from
the chart and pharmacy records.
RESULTS: PTSD was the primary diagnosis for each drug
as follows: Fluoxetine 16%, nefazodone 52%, paroxetine
24%, and sertraline 10%. The average daily dose of each
drug for depression vs. PTSD is as follows: Fluoxetine
23.8 mg vs. 31.3 mg; nefazodone 291.7 mg vs. 341.0 mg;








vs. 100.1 mg. Differences in doses were tested using lin-
ear models with a normal error distribution. Differences
in frequency of use were tested using categorical data
models (models of population homogeneity). Statistical
significance (p  .05) was achieved only on the frequency
with which nefazodone is used to treat PTSD and depres-
sion, as compared to other drugs. Statistical significance
of dose differences was not achieved due to a large varia-
tion in dosing of each drug.
CONCLUSION: At this medical center, nefazodone is
used significantly more frequently for PTSD than the SS-
RIs. Since severity of diagnosis and outcomes were not
included in this study, no conclusion can be made regard-
ing differences in efficacy between the groups. A poten-
tial pharmacotherapeutic advantage of nefazodone as a
treatment for PTSD is its proposed efficacy in treating
disorders commonly comorbid with PTSD, such as de-
pression, panic, anxiety, agitation, and sleep disturbance.
PMH24
HEALTH-CARE RESOURCE USE AMONG 
CAREGIVERS OF PEOPLE 
WITH SCHIZOPHRENIA
White RE1, Boscoe AN1, Travers J1, McDonnell DD2
1AstraZeneca, Wilmington, DE, USA; 2Consumer Health 
Sciences, Princeton, NJ, USA
OBJECTIVES: With increasing medical costs, the health
of schizophrenia caregivers cannot be ignored. This re-
search evaluated health-care resource use among care-
givers of people with varying severities of schizophrenia.
METHODS: In June 2000, 376 schizophrenia caregivers
from national support groups completed self-administered
questionnaires. They reported whether they were hospi-
talized (17%), visited the ER (19%), or had physicians’
appointments (48%) in the past six months. Caregivers
rated schizophrenia severity by reporting how often (on a
scale from 0 to 4) their patient experienced 23 problems.
Scores were then computed as the overall mean. Logistic
regression was used to control for other variables that
could confound resource use: caregivers’ demographics as
well as overall mental and physical health; patients’ demo-
graphics; time with schizophrenia, and antipsychotic use.
RESULTS: Controlling for these confounders, caregivers
of people with severe schizophrenia were about three times
more likely to have been hospitalized (OR  2.8, p 
.001) or to have visited an ER (OR  3.1, p  .001) in the
previous six months. The effect of severity on the number
of physician visits was not significant (p  0.798).
CONCLUSIONS: Medications and other strategies that
help control patients’ severity, or that help maintain peo-
ple at lower severity may reduce caregivers’ use of hospi-
tals and emergency rooms and ultimately lower the over-
all costs associated with treating schizophrenia.
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MENTAL WELL-BEING AMONG CAREGIVERS OF 
PEOPLE WITH SCHIZOPHRENIA
Travers J1, White RE1, Boscoe AN1, McDonnell DD2
1AstraZeneca, Wilmington, DE, USA; 2Consumer Health 
Sciences, Princeton, NJ, USA
OBJECTIVES: Caregivers’ mental health, and the effect
of schizophrenia severity, may be critical to patients’
quality of care. This research therefore evaluates how the
symptoms of schizophrenia affect the mental well being
of those providing informal patient care.
METHODS: In June 2000, 376 schizophrenia caregivers
from national support groups completed self-adminis-
tered questionnaires. Mental well being was measured us-
ing the SF-12. Schizophrenia symptoms were evaluated as
a four-level variable: high negative/high positive (35%);
high negative/low positive (17%); low negative/high posi-
tive (10%); low negative/low positive (38%). To control
for confounders to caregivers’ well being—caregivers’ de-
mographics and involvement, and patients’ demographics
and time with schizophrenia—a linear regression model
was used.
RESULTS: The mean SF-12 score was 48.7 (SD 
 10.6).
In bivariate, chi-squared analysis, caregivers’ mental well
being decreased as schizophrenia symptoms increased
(p  .001). Controlling for confounders, symptom sever-
ity remained significant. Caregivers of people with low
positive and negative symptoms had average SF-12 scores
six points higher than those caring for people with high
symptoms (p  .001). Even caregivers of people with
only high positive symptoms scored about five points
higher (p  0.015).
CONCLUSIONS: Caregivers of people with high nega-
tive symptoms did not differ from those with both high
negative and positive symptoms (p  0.616). Medica-
tions and strategies that help control patients’ symptoms,
especially negative symptoms, can also help caregivers
experience more positive well being.
RESPIRATORY DISORDERS
PRP1
A COMPARISON OF SIX PHONE INTERVIEWS 
DESIGNED TO MEASURE HEALTH-RELATED 
LOST PRODUCTIVE TIME AT WORK
Ricci J, Stewart WF, Leotta CR, Chee E
AdvancePCS, Hunt Valley, MD, USA
OBJECTIVE: To evaluate variations in work-loss esti-
mates by phone interview method. 
METHODS: In phone interviews, total work loss estimates
were based on three domains: missed workdays; missed
hours, and reduced productivity on days at work while not
feeling well. Three different phone interviews were devel-
oped. Version 1 (V1) included a lengthy direct assessment of
work loss. Version 2 (V2) was an abridged version of V1.
Version 3 (V3) included a brief indirect assessment of work
loss. Two recall periods at one week and at four weeks were
also tested. Combining the three versions and the two recall
periods yielded six different interviews. A convenience sam-
